Sugi Predict

Sugi Predict / Compounds / SCHEMBL3697678

SCHEMBL3697678

SCHEMBL3697678

CC1(C)OB(c2cnc(NC(=O)O)s2)OC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.44
▸ PKM P14618 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 6/20 0.38
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ NPC1 O15118 7/20 0.37
▸ RAB9A P51151 7/20 0.37
▸ PAX8 Q06710 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NR3C1 P04150 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28458171 0.81 USP30 (0.56) USP30SMN1; SMN2CCNE1CDK2CA1
SCHEMBL12715453 0.74 USP30 (0.43) USP30
SCHEMBL19031383 0.73 ABL1 (0.44) LMNASMN1; SMN2CCNE1CDK2CDK5
SCHEMBL20388812 0.72 USP30 (0.46) USP30PKMSMN1; SMN2KMT2AGAA
SCHEMBL15897514 0.71 USP30 (0.43) USP30CA1CA2CA9
SCHEMBL17799957 0.71 PDGFRB (0.44) CA1CA2CA9PDGFRBKDR
SCHEMBL2379522 0.71 USP30 (0.43) USP30MEN1KMT2A
SCHEMBL29354508 0.71 PDGFRB (0.37) PKMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL21384075 0.71 PDGFRB (0.37) PKMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL3794688 0.70 RAB9A (0.62) PKMLMNASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4469035-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE Bridgene Biosciences, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146786-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. (US) 2023-08-03 — — WO disclosed
EP-3416960-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2021-12-01 — — EP disclosed
EP-3313832-B1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2021-02-24 — — EP disclosed
US-10640498-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2020-05-05 — — US disclosed
US-10544130-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-01-28 — — US disclosed
US-20190144432-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-05-16 — — US disclosed
US-10221163-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-05 — — US disclosed
US-20190055232-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED (GB) 2019-02-21 — — US disclosed
EP-3416960-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2018-12-26 — — EP disclosed
WO-2016210215-A1 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 — — WO disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 — — EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 — — US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 — — WO disclosed
EP-2406258-B1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LTD (GB) 2014-12-03 — — EP disclosed
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED 2014-10-02 — — US disclosed
US-8785457-B2 Pyrimidine derivatives as mTOR inhibitors CELLZOME LIMITED (GB) 2014-07-22 — — US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
WO-2010103094-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LIMITED (GB) 2010-09-16 — — WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544130-B2 Metallo-beta-lactamase inhibitors MLX, ZFX, MMP12 USP30 2066/4885PKM 3517/4885LMNA 1971/4885
US-10640498-B2 Compounds USP30, USP20, UBQLN1 USP30 1/4885PKM 2189/4885LMNA 3830/4885
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS MTOR, RICTOR, RPTOR USP30 3803/4885PKM 402/4885LMNA 2684/4885
US-10221163-B2 Metallo-beta-lactamase inhibitors MLX, ZFX, MMP12 USP30 2092/4885PKM 3486/4885LMNA 2038/4885
US-20190055232-A1 NOVEL COMPOUNDS USP30, USP20, USP28 USP30 1/4885PKM 2452/4885LMNA 3926/4885
US-20190144432-A1 METALLO-BETA-LACTAMASE INHIBITORS MLX, ZFX, MMP12 USP30 2066/4885PKM 3517/4885LMNA 1971/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 USP30 2275/4885PKM 1189/4885LMNA 4636/4885
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA USP30 2030/4885PKM 2536/4885LMNA 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.